Evidence-based products

Study claim: SuperCitrimax, a calcium/potassium (-)-hydroxycitric acid extract derived from a South Asian fruit, increases the activity of genes involved with carbohydrate and fat metabolism, making it a unique weight-loss ingredient.

Published: Rink Roy S, et al. Body weight and abdominal fat gene expression profile and response to a novel hydroxycitric acid-based dietary supplement. Gene Expression 2004; 11:251-62.

Abstract: The study was conducted to determine the effects of SuperCitrimax on body weight and the expression of genes in abdominal fat tissue. The tissue is of interest because excess fat in the abdomen increases the risk of cardiovascular disease.
Adult Sprague-Dawley rats received 10mg of Super Citrimax per kg of body weight, an amount corresponding to low-dose consumption in humans (about 600mg for a 132lb person). After eight weeks, the animals had a modest but significant decrease in body weight compared to placebo-fed animals. DNA micro-array analysis identified more than 9,900 genes and ESTs (fragments of DNA sequence) present in abdominal fat. About one per cent of those identified were found to be sensitive to SuperCitrimax, while none of the genes that support fundamental tissue processes were adversely affected. In total, 93 genes were up-regulated and 18 were down-regulated in the fat tissue of the supplemented animals. SuperCitrimax also up-regulated a family of genes involved in the signalling activity of serotonin, a brain chemical that affects sleep, mood and appetite control. This corroborated earlier studies in animals and humans showing SuperCitrimax increases serotonin levels, reducing appetite and body weight.

Potential applications: Made by InterHealth, for use as a dietary supplement to aid weight management.

More info:
+1 707 751 2800

Study claim: Early intervention with a standardised preparation of Echinacea purpurea (Echinilin) decreases the average severity and duration of the common cold.

Published: Goel, V, et al. Efficacy of a standardized echinacea preparation (EchinilinTM) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. Clin Pharm & Therapeu 2004; 29(1):75-83.

Abstract: Although a popular herb to treat cold symptoms, results from a limited number of clinical trials have had inconclusive results, perhaps due to the use of poorly standardised echinacea products. Therefore, for this study, a formulation containing alkamides, cichoric acid and polysaccharides at concentrations of 0.25, 2.5 and 25mg/mL, respectively, was prepared from freshly harvested Echinacea purpurea plants (Echinilin). In this randomized, double-blind, placebo-controlled trial, 282 subjects aged 18-65 years with a history of two or more colds in the previous year, but otherwise in good health, were recruited. The subjects were randomised to receive either echinacea or placebo. They were instructed to start the echinacea or placebo at the onset of the first symptom related to a cold, consuming 10 doses the first day and four doses per day on subsequent days for seven days. Severity of symptoms (10-point scale) and dosing were recorded. A nurse examined the subjects on the mornings of days three and eight of their cold. A total of 128 subjects contracted a cold (59 echinacea, 69 placebo). The total daily symptom scores were found to be 23 per cent lower in the echinacea group than in placebo in those who followed all elements of the study protocol (P
Potential Applications: Sold by Factors R&D Technologies as a raw material for dietary supplements, and as finished products, in extracts and soft gels.

More info:
+1 866 420 4101

To submit newly published research on your company?s ingredients, please email [email protected] for details.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.